EKF Diagnostics Holdings posts revenue rise

Healthcare company EKF Diagnostics Holdings on Friday posted a 20 per cent increase in revenues for the second half of 2012.

Healthcare company EKF Diagnostics Holdings on Friday posted a 20 per cent increase in revenues for the second half of 2012.

In a trading update ahead of its results for the financial year ended December 31st, EKF said the second half wielded unaudited revenues of £26.1m, up from £21.7m the year before.

The company reported a net cash position of £2.3m for the year while earnings before interest, taxes, depreciation, and amortization (EBITDA) were expected to be ahead of previous upgraded market consensus.

Results were bolstered by sales of higher margin reagents including its chemical, beta-hydroxybutyrate.

The second half gained from sales of HemoPoint H2 instruments and cuvette through its distribution partner, Alere.

Alere sold 2,460 HemoPoint H2 instruments into the North American market compared to 608 sold by Stanbio in the previous year.

Towards the end of the year EKF received further orders from the Mexican Institute of Social Security (IMSS), for cuvettes for the HemoPoint H2. It followed a $3.6m order from IMSS in November.

Julian Baines, Chief Executive of of EKF, said: "I am delighted with the strong performance shown by the business in 2012. Our continued focus on margin improvement has delivered EBITDA which is again ahead of expectations as well as strong cash generation.

"Looking forward, the contract from IMSS and the strong sales of Quo-Test and Quo-Lab we've recorded in January marks a confident start to 2013."

Shares rose 7.27% to 29.50p at 10:53 Friday.

RD

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021
Four investment trusts for income investors to buy now
Investment trusts

Four investment trusts for income investors to buy now

Some high-yielding listed lending funds have come through the crisis with flying colours. David Stevenson picks four of the best.
12 Apr 2021